News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Discontinued
Johnson & Johnson (JNJ) Quits Multibillion-Dollar Hep C Drug Program, Partners' Stocks Fall 9/13/2017
Unknown Number of Employees Impacted as ESSA Pharma Restructures and Refocuses R&D 9/11/2017
Regeneron (REGN) Jumps Despite Ditching Development Of RSV Med 8/14/2017
Alexion (ALXN) Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint (BPMC) and Arbutus Biopharma (ABUS) 7/28/2017
GlaxoSmithKline (GSK) CEO Kills 30+ Pre-Clinical and Clinical Programs 7/28/2017
Brace Yourself: GlaxoSmithKline (GSK)'s New CEO Gets Ready to Overhaul the Drug Pipeline 7/25/2017
e-Therapeutics' New CEO Takes The Ax To Four Drug Discovery Programs 7/24/2017
More Deaths Lead Seattle Genetics (SGEN) to Discontinue Phase III Leukemia Study 6/21/2017
XBiotech (XBIT) Plunged 66% After Discontinuing Phase III Colorectal Cancer Study 6/12/2017
Stock Tanks as Endocyte (ECYT) Cuts 40% of Workforce, Slashes 2 Clinical Programs 6/5/2017
Daiichi Sankyo Abandons 6 Clinical Programs in Q1 Update 5/12/2017
Astellas (ALPMY) Dumps Lung Cancer Program After Phase III Data Fails To Impress 5/11/2017
Dimension Therapeutics (DMTX) Throws In The Towel On Hemophilia B Drug 5/10/2017
Pfizer (PFE) Axes 3 Drugs From Pipeline in Q1 5/4/2017
AstraZeneca PLC (AZN) Dumps Two Drugs From Pipeline, Causing an Ex-Partner's Stock to Tank Some More 4/28/2017
Genentech (RHHBY) Quietly Shelves Phase II Cancer Contender 4/28/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study 4/18/2017
Novogen (NVGN) Terminates Preclinical Program, Will Cut an Undisclosed Number of Jobs 4/6/2017
Juno (JUNO) Finally Drops Problem CAR-T Drug That Caused Deaths 3/3/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016
Top 7 Jaw-Dropping Pipeline Blowups This Year 12/5/2016
SoCal's Arrowhead Pharma (ARWR) Stock Craters After Terminating 30% of Workforce, Discontinuing Work on Lead Hep B Drugs 12/1/2016
Pfizer (PFE) Abandons Cholesterol Drug Bococizumab, Writes it Off as an Earnings Loss 11/3/2016
In 3Q Report, Shire (SHPG) Breaks Out Data From Baxalta (BXLT) Acquisition and Announces Several Program Terminations 11/2/2016
Novo Nordisk A/S (NVO) Bids Adieu to Oral Insulin, Shakes Up R&D for Growth 11/1/2016
Biogen (BIIB) Quietly Kills Autoimmune Program 10/28/2016
23andMe Kills Its Next Generation Gene Sequencing Project, Cuts Jobs 10/27/2016
Shkreli Called it: Mast Therapeutics (MSTX) Begins Winding Down Vepoloxamer Programs 9/26/2016
Gilead (GILD) Terminates Phase II/III Study of Ulcerative Colitis Drug 9/23/2016
Struggling AVEO Oncology (AVEO) Quietly Discontinues Phase II Ficlatuzumab Study 9/13/2016
Merck & Co. (MRK) Terminates Development of Osteoporosis Drug Due to Stroke Risk 9/2/2016
Shire (SHPG) Kills Baxalta (BXLT)'s Hemophilia B Program; Clears Path for BioMarin (BMRN), Spark Therapeutics (ONCE) and uniQure (QURE) 8/4/2016
Tokai Pharma (TKAI) to Terminate ARMOR3-SV Clinical Trial, Shares Tank 7/26/2016
Citius Pharma Discontinues Development of Weight Loss Drug Suprenza 7/5/2016
UK Drugs Regulator Halts Approvals for Quest Life Sciences 7/1/2016
Mologen (MOLGF.PK) Restructures, Pushes Immunology Program, Shelves Renal Cancer Vaccine 6/9/2016
All Eyes Turn to Sarepta (SRPT) as BioMarin (BMRN) Shutters Its Kyndrisa Duchenne Program 6/2/2016
In Light of Disappointing Trial Results, Acorda (ACOR) Terminates Epilepsy Drug Program 5/20/2016
Clovis Oncology (CLVS) to Eliminate 35% of Workforce and Ends All Trials of Lung Cancer Drug Rociletinib 5/9/2016
Janssen R&D Discontinues Fulranumab Phase III Program; Terminates Agreement with Amgen (AMGN) 4/4/2016
Array BioPharma (ARRY) to Abandon Testing of Ovarian Cancer Drug 4/1/2016
Peregrine (PPHM) Stock Crashes After Company Terminates Phase III Trial for Bavituximab 2/29/2016
SoCal's Ignyta (RXDX) Ceases Development of Certain Drug Programs to Focus on Priority Pipeline 2/24/2016
GlaxoSmithKline (GSK) Kills U.S. Part of Eczema Treatment Deal With Basilea (BSLN.SW) 1/22/2016
KaloBios (KBIO) Fires Martin Shkreli, UC Davis Suspends Leukemia Trial Due to Shkreli 12/23/2015
Janssen Pharmaceutical, Medivir (MVRBF) Terminate AL-704 Phase I for Treatment of Hepatitis C 12/22/2015
Nuvo Research (NRI.TO) to Discontinue all WF10 Development 12/21/2015
Threshold Pharma (THLD) Crumbles as Merck KGaA (MKGAF.PK) Abandons Cancer Drug After Trial Failures 12/7/2015
Fate Therapeutics (FATE) Discontinues Development of ProHema in Patients Undergoing Cord Blood HCT 12/7/2015
Amidst Job Growth and Strong Stocks, Eli Lilly (LLY) Terminates BIL Diabetes Program 12/4/2015
Aptose Biosciences Suspends Dosing of Lead Drug APTO-253 11/20/2015
Medivir (MVRBF) Terminates the ADAM8 Inhibitor Project for Pancreatic Cancer 11/17/2015
NeuroVive (NVP)'s OCB-030 Preclinical Program Has Been Discontinued By Arbutus Biopharma (ABUS) 10/28/2015
XenoPort (XNPT) Chops Jobs, Replaces CEO and Shifts Focus in Restructuring 10/5/2015
Zosano (ZSAN) Terminates Eli Lilly (LLY) Deal, Halts Daily Osteoporosis Drug Program 9/29/2015
GI Dynamics (GID.AX) Discontinues U.S. Trial of EndoBarrier Therapy 7/30/2015
La Jolla Pharma (LJPC) Bails On Two Drug Programs, Shifts Focus to Rare Disease 5/11/2015
Alkermes plc (ALKS) Discontinues Development of Pain Drug 2/24/2015
Chimerix, Inc. (CMRX) Abandons Testing of Experimental Ebola Drug in Liberia 2/3/2015
Merck & Co. (MRK) to Stop Selling Once-Hot Hep C Drug Victrelis 1/27/2015
Infinity Pharmaceuticals Inc. (INFI) to Stop Developing Rheumaid Arthritis Drug 1/9/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Discontinues Lung Infection Drug, Stock Sinks 1/7/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Reports Top-Line Data For Phase 2 Study Of KB001-A To Treat Pseudomonas Aeruginosa Lung Infections In Cystic Fibrosis Patients 1/7/2015
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
H. Lundbeck A/S (LUN.CO) Will Halt Studies Into Vampire Bat Saliva Drug 12/19/2014
Teva Pharmaceutical Industries Limited (TEVA) To Stop R&D In Cancer And Women's Health; 14 Pipeline Projects To End, Divest 10/7/2014
Trial Failures Force Eli Lilly and Company (LLY) To Terminate Development Of Tabalumab 10/6/2014
Traders Wobble On Merck KGaA (MKGAF.PK) After Stimuvax Stop 9/12/2014
Bay Area's Hyperion Therapeutics (HPTX) Tanks As Employee Misconduct Leads To Drug Trial Halt 9/10/2014
Second Failure Of The Month As Targacept, Inc. (TRGT) Halts Development Of Bladder Drug, Shares Plunge 7/30/2014
Takeda Pharmaceutical Co. Ltd. (TKPYY) Terminates Development Of Top Prostate Cancer Prospect Orteronel 6/20/2014
Johnson & Johnson (JNJ) Halts Development Of Botox Rival, Axes Staffers 4/15/2014
Forest Laboratories, Inc. (FRX) To Discontinue NAMENDA® Tablets, Focus On Once-Daily NAMENDA XR® 2/17/2014
Sanofi (France) (SAN.PA) Suffers Another Setback, Ditches Late-Stage Bone Marrow Cancer Drug 11/19/2013
Imprimis Pharmaceuticals (immy) to Shift Focus, Discontinues Impracor Phase 3 Program to Focus on Other Areas 11/6/2013
ImmunoGen (IMGN) Discontinues Study as Lung Cancer Drug Flops; Stock Crashes -18.97% at Market Close (November 5, 2013) 11/6/2013
Ariad Pharmaceuticals, Inc. (ARIA) Discontinues Phase 3 Study of Cancer Drug Iclusig; Shares Decimated, Falls -40.67% at Market Close (October 18, 2013) 10/22/2013
Medivir AB (MVIRb.F), Daewoong Pharmaceutical Co., Ltd. Discontinue Hepatitis B Drug Development 9/6/2013
Medivir AB (MVIRb.F) Makes Strategic Decision to Discontinue its NS5A Inhibitor Program 8/15/2013
Albany Molecular Research, Inc. (AMRI) (AMRI): Bristol-Myers Squibb Company (BMY) Stops Development of Depression Drug 8/14/2013
Isis Pharmaceuticals, Inc. (ISIS) Ditches Rheumatoid Arthritis Drug After Phase 2 Trial Disappoints 8/6/2013
Higher Death Rates Force Celgene Corporation (CELG) to End Blood Cancer Trial 7/22/2013
Roche (RHHBY) Halts Diabetes Drug Trial in Blow to Pipeline 7/12/2013
Roche (RHHBY) Backs Out on Seaside Therapeutics Drug Trial for Fragile X. Parents Dismayed 6/11/2013
Sanofi (France) (SAN.PA) Pulls the Plug on Two Late-Stage Drugs, Plans $285 Million Charge 6/4/2013
Pfizer Inc. (PFE) Halts Study of Non-Hodgkin's Lymphoma Drug 5/29/2013
Merck & Co., Inc. (MRK) Drops Development of Parkinson's Drug 5/28/2013
Eli Lilly and Company (LLY) to Take $30 Million Charge After Cancer Drug Fails Phase 3 Trial 5/15/2013
CytRx Corporation (CYTR) Ditches Lung Cancer Drug After Phase 2 Trial Failure 5/10/2013
Bayer AG (BAY.F) Halts Study of Hemophilia Therapy BAY 86-6150 Due to Safety Concerns 5/7/2013
Celltrion, Inc. Drops Late-Stage Trial of Roche (RHHBY) Rituxan Drug Copy 4/19/2013
Liver Toxicity Brings Melanoma Study on Bristol-Myers Squibb Company (BMY)/Roche (RHHBY) Drugs to a Halt 4/4/2013
Clavis Pharma ASA Stops Elacytarabine Development on Negative Ph3 Trial in AML 4/3/2013
ZIOPHARM Oncology, Inc. (ZIOP.OB) Cancer Drug Fails in Late-Stage Trial; Shares Plunge 3/27/2013
BioLineRx Ltd. Says CLARITY Trial of BL-1020 Did Not Meet Primary Efficacy Endpoint, to Discontinue Study 3/21/2013
Pfizer Inc. (PFE) Halts Development of Hepatitis C Drug 3/19/2013
Moberg Derma Discontinues Clinical Development of Limtop 3/11/2013
AEterna Zentaris (AEZS) to Discontinue Phase 3 Trial in Multiple Myeloma With Perifosine 3/11/2013
FDA Halts Amgen (AMGN) Trial After Teen Death 3/4/2013
Amgen (AMGN), UCB, Inc. (UCBJF.PK) Halt Testing of Fracture-Healing Drug 2/13/2013
Eli Lilly and Company (LLY) to Cease Tabalumab Phase 3 RA Program 2/8/2013
Idenix Pharmaceuticals, Inc. (IDIX) Halts Development of Two Hepatitis C Treatments 2/6/2013
Vanda Pharmaceuticals, Inc. (VNDA) to Stop Developing Anti-Depressant 2/1/2013
What Merck & Co., Inc. (MRK) Told Doctors About Tredaptive Before It Stopped Selling It 1/15/2013
Merck & Co., Inc. (MRK) Pulls Tredaptive Cholesterol Pill After a Flop 1/14/2013
Tranzyme Pharma (TZYM) Stops Mid-Stage Gastric Study After Drug Fails 12/18/2012
Boehringer Ingelheim Corporation Ends Phase 2 Trial of Dabigatran in Mechanical Valve Patients 12/13/2012
Geron Corporation (GERN) Ends Brain Cancer Drug Study, Cuts 43 Jobs 12/10/2012
Bristol-Myers Squibb Company (BMY) Drops Alzheimer's Drug on Little Benefit 12/5/2012
Ranbaxy Laboratories (RANBAXY.BO) Halts Production of Generic Lipitor 12/3/2012
Merck & Co., Inc. (MRK) Shelves Development of Another Diabetes-Cholesterol Program 11/14/2012
Roche (RHHBY)'s Good Cholesterol Drug Shows Negative Side Effects 11/7/2012
Bioniche Life Sciences Inc. (BNC) Discontinues Current Phase 3 Clinical Trial With Urocidin™ 11/5/2012
Ex-Geron Corporation (GERN) CEO Launches Effort to Revive Lost Stem Cell Program 10/29/2012
Abbott Laboratories (ABT), Reata Pharmaceuticals, Inc. Kidney Disease Drug Trial Stopped 10/22/2012
Novartis AG (NVS) Stops Developing Long-Acting Version of Vanda Pharmaceuticals, Inc. (VNDA)'s Fanapt 10/12/2012
Oxford BioMedica PLC (OXB.L) Abandons Prostate Cancer Vaccine Study 10/11/2012
Anacor Pharmaceuticals, Inc. Says GlaxoSmithKline (GSK) Stops Development of Antibiotic 10/8/2012
ArQule, Inc. (ARQL), Daiichi Sankyo, Inc. (4568.t) Discontinue Lung Cancer Drug Trial 10/3/2012
Novo Nordisk A/S (NVO) Halts Development of Hemophilia Drug 10/2/2012
Vertex Pharmaceuticals (MA) (VRTX) Ends Work on One Hepatitis C Drug, Continues Another 9/26/2012
Astex Pharmaceuticals (ASTX) Ends Development of Lung Cancer Drug 9/24/2012
Targacept, Inc. (TRGT) to Cut More Jobs, Halt ADHD Drug Development After Failed Phase 2 Trial 9/18/2012
Johnson & Johnson (JNJ) Ends Trial of Skin-Disorder Drug Over Adverse Events 9/17/2012
Lundbeck Inc. (LUN.CO) Halts Sales of Leukemia Drug Over Supply Problems 9/17/2012
Geron Corporation (GERN) Ends Breast Cancer Study of Imetelstat 9/11/2012
Zalicus Inc. (ZLCS) to Halt Further Clinical Development With Synavive 9/10/2012
Palatin Technologies (PTN) Says Partner AstraZeneca PLC (AZN) to Halt Further Development of Obesity Drug 9/10/2012
Eli Lilly and Company (LLY) Ends Development of Schizophrenia Drug 8/30/2012
Bristol-Myers Squibb Company (BMY) Ends Hepatitis C Development After Patient Death; Eats a $1.8 Billion Loss 8/27/2012
Gilead Sciences, Inc. (GILD) Stops Development of PAH Drug After Missing Study Goal 8/23/2012
Pfizer Inc. (PFE), Johnson & Johnson (JNJ) Scrap Alzheimer's Drug After Phase III Study Fails 8/8/2012
Infinity Pharmaceuticals Inc. (INFI) Pulls Plug on Cancer Drug Saridegib Trials 6/19/2012
BioInvent (BOVNF), ThromboGenics NV (TBGNF) Plunges as Development of Anticoagulent is Dropped 6/5/2012
Chelsea Therapeutics, Inc. (CHTP) Halts Development of Arthritis Drug 6/1/2012
Q-Med AB Discontinues the Breast Indication for Macrolane 4/17/2012
SciClone Pharmaceuticals, Inc. (SCLN) to Discontinue Development of SCV-07 Oral Mucositis Trial 3/7/2012
Karo Bio AB Axes Clinical Dyslipidemia Program After Side Effects Surface in Animal Study 2/15/2012
Theratechnologies Inc. (TH.TO) Cuts 60% of Workforce, Refocus for 2013 12/7/2011
Sanofi (France) (SASY.PA) Discontinues Selling Authorized Generic Version of Lovenox 12/5/2011
National Institutes of Health (NIH) Discontinues Tenofovir Vaginal Gel in 'Voice' HIV Prevention Study 11/29/2011
Celgene International Sárl (CELG) Will Discontinue Phase III MAINSAIL(R) Trial in Castrate-Resistant Prostate Cancer 11/28/2011
Moberg Derma Discontinues Preclinical Development Program for A-Fizz 10/27/2011
Conatus Pharmaceuticals Inc.Terminates Phase 2 Clinical Trial of CTS-1027 10/27/2011
Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Drops Europe Development of Insomnia Drug 10/10/2011
Sangamo BioSciences, Inc. (SGMO) Shares Plunge on Diabetic Neuropathy Drug Failure, to Terminate Development 10/4/2011
Astellas Pharma Inc. (YPH.BE) Halts Development of Anti-Clotting Drug 9/29/2011
FDA Issues Clinical Hold on Cancer Drug by Immunomedics, Inc. (IMMU) 9/26/2011
Eisai Inc. (ESALF.PK) Discontinues Global Development of Rabeprazole Sodium Extended-Release Capsules, 50 mg 9/6/2011
Shire plc Falls After Scrapping Dermagraft as Leg Ulcer Therapy 8/25/2011
Endo Pharmaceuticals (ENDP) Terminates Pain Program After Failed Trial; Ends Pact With Grunenthal GmbH 8/19/2011
Amylin Pharmaceuticals, Inc. (AMLN), Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Halt Obesity Drug Development Following Commercial Reassessment of the Program 8/8/2011
Merck & Co., Inc. (MRK) to Cut Up to 13,000 Jobs, Q2 Profit Rises; Discontinues Ph3 Migraine Program 8/4/2011
BeiLu Pharma Gives Up on Melatonin-based Depression Drug 7/19/2011
Lack of Partner Prompts Genmab A/S (GEN.CO) to Drop Zalutumumab 6/28/2011
Diamyd Medical AB Discontinues US Phase III Trial with Type I Diabetes Product 6/24/2011
Enzon Pharmaceuticals, Inc. (ENZN) Ditches PEG-SN38 for mCRC but Continues Development in Other Cancers 5/19/2011
Drugmakers Including Johnson & Johnson (JNJ) and Procter & Gamble (PG) Eliminate Infant Drops of Key Medicine 5/5/2011
Pfizer Inc. (PFE) Stops Making Canine Tick Med Over Side Effects 4/25/2011
Galapagos NV (GLPG.BR) Discontinues Phase II Trial for GLPG0259, Focuses Resources on Other Rheumatoid Arthritis Programs 4/15/2011
StemCells Inc. (STEM) Discontinues Batten Disease Program 4/8/2011
AstraZeneca PLC (AZN) Pulls Bloodthinner In France 3/24/2011
AstraZeneca PLC (AZN) Pulls Asthma Product, Hitting SkyePharma Inc. (SKYE) 3/7/2011
Innate Pharma Drops IPH 1101 Development 3/4/2011
Pfizer Inc. (PFE) Drops 15 Pipeline Projects 3/1/2011
Sanofi-Aventis (France) (SASY.PA) to Withdraw Anzemet From Five Countries 2/15/2011
Idenix Pharmaceuticals, Inc. (IDIX) Cancels Hepatitis C Drug On Toxicity Worries; Shares Fall 2/10/2011
Hospira, Inc. (HSP) to Stop Making Drug Used in Executions 1/24/2011
Genentech (RHHBY) Informs Customers of Important Information About Triad Group's Alcohol Prep Pads 1/14/2011
More Evidence Links Roche (RHHBY)'s Avastin to Heart Failure in Breast Cancer Patients 1/6/2011
Ipsen Closes BIM 23A760 Phase II Trials For Acromegaly; Compound Does Not Meet Expectations 12/15/2010
Servier's Diabetes Drug, Mediator May Be Linked to 500 Deaths 11/16/2010
Transition Therapeutics Inc. (TTH.TO) and Eli Lilly and Company (LLY) Stops Diabetes Drug Development 9/17/2010
Basilea Pharmaceutica (BSLN.SW) Announces Discontinuation of Sale of Ceftobiprole by Janssen-Cilag AG, a Johnson & Johnson (JNJ) Company, In Switzerland 9/9/2010
Karo Bio AB Announces That Merck & Co., Inc. (MRK) Discontinues Development of Mk-6913 for Hot Flashes 9/8/2010
Shire Pharmaceuticals (SHPGY) to Pull Low Blood Pressure Drug from Market 8/18/2010
Teva Pharmaceutical Industries Limited (TEVA) Lays Off 70 as Propofol is Abandoned 8/16/2010
Pfizer Inc. (PFE) Pulls Leukemia Drug Mylotarg From U.S. Market After Deaths, No Proven Benefit 6/22/2010
Trubion Pharmaceuticals Inc. (TRBN) Says Pfizer Inc. (PFE) to Stop Development of Arthritis Drug, TRU-015 6/15/2010
Teva Pharmaceutical Industries Limited (TEVA) To Stop Manufacturing Propofol Sedative 5/28/2010
FDA Says Asthma and COPD Inhalers That Contain Ozone-depleting CFCs to be Phased Out; Alternative Treatments Available 4/14/2010
GenVec Inc. (GNVC) Says Cancer Drug Not Effective, Ends Trial 3/30/2010
Novelos Therapeutics, Inc. (NVLT) Discontinues Current Development Program for NOV-002 in NSCLC; Primary and Secondary Endpoints Not Met in Phase 3 Trial 3/18/2010
Pfizer Inc. (PFE) (JOBS) Drops 100 Drugs from Pipeline 1/29/2010
Pfizer Inc. (PFE) (JOBS) Ends Late-stage Lung-Cancer Study; Analysis Showed it Would Miss Main Goal 12/30/2009
Arena Pharmaceuticals, Inc. (ARNA) Announces Merck KGaA (MKGAF.PK) Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis 12/28/2009
Sanofi-Aventis (France) (SASY.PA) Stops Development of Two Drugs: Eplivanserin in Insomnia and Thrombosis Drug Idrabiotaparinux 12/21/2009
BioMS Medical (MS.TO) Provides Corporate Update; Company will Not Pursue Further Late Stage Clinical Trials with Dirucotide in MS 12/18/2009
Thallion Pharmaceuticals Inc. Discontinues Phase II Glioblastoma Multiforme Trial After Review of Interim Data 12/18/2009
Seattle Genetics, Inc. (SGEN) (JOBS) Stops Mid-Stage Cancer Trial 10/6/2009
SciClone Pharmaceuticals, Inc. (SCLN) (JOBS) Drops Cancer Drug Development 10/5/2009
ZymoGenetics, Inc. (ZGEN) (JOBS) Says Merck Serono Discontinues MS Trials 9/29/2009
Merck & Co., Inc. (MRK) (JOBS) Abandons One Migraine Drug MK-3207, Pursues Another 9/11/2009
Antisoma PLC (ASM.L) Announces Discontinuation of Development of AS1402 8/10/2009
Insmed Incorporated (INSM) Stops Supplying Iplex To New Patients 7/27/2009
Repros Therapeutics Inc. (RPRX) to Stop Using 50 mg Dose in Fibroids Study 7/1/2009
UCB Group (UCBJF.PK) and Biogen Idec, Inc. (Massachusetts) (BIIB) Discontinue Phase II Clinical Trial of CDP323 7/1/2009
Roche Holding AG (RHHBF.PK) Stops Selling Acne Drug Accutane 6/30/2009
ImmunoGen, Inc. (IMGN) to End Stomach-Cancer Drug Development 6/15/2009